Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18736621 | TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGS | June 2024 | September 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18594231 | OCULAR LUBRICANT FORMULATIONS | March 2024 | August 2025 | Allow | 17 | 1 | 0 | No | No |
| 18575483 | CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS | December 2023 | February 2025 | Allow | 14 | 1 | 1 | No | No |
| 18514612 | TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE (AD) | November 2023 | August 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18499240 | ASTAXANTHIN PICKERING EMULSION WITH COLON TARGETED DELIVERY FUNCTION, AND PREPARATION METHOD AND APPLICATION METHOD THEREOF | November 2023 | October 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18385805 | Method of Dispersing Hydrophobic Substances in Aqueous Cleansing System | October 2023 | February 2026 | Allow | 27 | 3 | 0 | Yes | No |
| 18379964 | 6'-(3-CHLOROPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDS | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18463734 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | September 2023 | November 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18462245 | AGOMELATINE ORAL TRANSMUCOSAL FILM | September 2023 | January 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18278726 | HAIR GROWTH AGENT | August 2023 | February 2026 | Abandon | 30 | 0 | 1 | No | No |
| 18235256 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODS | August 2023 | December 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18449747 | SEMI-SOLID TOPICAL COMPOSITION CONTAINING PIRFENIDONE AND MODIFIED DIALLYL DISULFIDE OXIDE (M-DDO) FOR ELIMINATING OR PREVENTING ACNE | August 2023 | June 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18208279 | Crushable Capsule Beads Containing Cuticle Moisturizing Oils | June 2023 | January 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18208186 | USE OF SODIUM THIOSULFATE (STS) WITH AND WITHOUT COFACTORS FOR THE TREATMENT OF INFLAMMATORY, NEURODEGENERATIVE AND NEUROPSYCHIATRIC CONDITIONS | June 2023 | December 2024 | Abandon | 18 | 4 | 0 | No | No |
| 18140124 | SLURRY AND SOLUTION COMPOSITIONS | April 2023 | June 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18308409 | ANTIMICROBIAL COATINGS FOR MEDICAL DEVICES | April 2023 | November 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18033087 | PROCESS FOR PRODUCING MICROPARTICLES LADEN WITH AN AROMA CHEMICAL | April 2023 | March 2026 | Abandon | 34 | 1 | 1 | No | No |
| 18134687 | TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGS | April 2023 | June 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18131871 | PYRACLOSTROBIN MICROCAPSULE BASED ON SODIUM ALGINATE AND PREPARATION METHOD | April 2023 | November 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 18174233 | Organic Compounds | February 2023 | June 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18100104 | ORALLY DISINTEGRATING TABLET COMPRISING AMORPHOUS SOLID DISPERSION OF NILOTINIB | January 2023 | October 2024 | Abandon | 20 | 2 | 0 | No | No |
| 18005300 | COMBINATION THERAPY WITH A MUTANT IDH1 INHIBITOR, A DEOXYADENOSINE ANALOG, AND A PLATINUM AGENT | January 2023 | December 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17998473 | KIT OF GEL-FORMING SOLUTIONS INTENDED FOR PREPARATION OF HYDROGEL BASED ON COVALENTLY CROSSLINKED HYDROXYPHENYL DERIVATIVE OF HYALURONAN FOR PREVENTION OF POSTOPERATIVE COMPLICATIONS RELATED TO FORMATION OF COLORECTAL ANASTOMOSIS, USE OF KIT, METHOD OF PREPARATION OF HYDROGEL AND USE THREREOF | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17982024 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AND METHODS OF USING THE SAME | November 2022 | October 2024 | Allow | 23 | 1 | 1 | No | No |
| 17967943 | Transdermal Double-layer Microneedle Based on Hydrogen Producing Probiotics and Its Preparation Method and Application | October 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 18047180 | NOVEL PHARMACEUTICAL COMPOSITION | October 2022 | May 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17917160 | CRYSTALLINE FORMS OF 3-CYANO-1-[4-[6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL]-1H-PYRAZOL-1-YL]CYCLOBUTANEACETONITRILE, AND USE THEREOF | October 2022 | May 2025 | Allow | 31 | 1 | 0 | No | No |
| 17936733 | COMPOSITION COMPRISING MELATONIN OR ITS DERIVATIVES WITH COENZYME Q10 AND USE THEREOF AGAINST AGEING OF THE SKIN | September 2022 | September 2023 | Abandon | 12 | 0 | 1 | No | No |
| 17995025 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | September 2022 | October 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17915021 | COMPOSITION COMPRISING ANTIMICROBIAL AGENT AND ITS USES | September 2022 | September 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17906473 | MICROCAPSULES COATED WITH A POLYSUCCINIMIDE DERIVATIVE | September 2022 | December 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17943998 | Self-Warming Hygienic Tissue | September 2022 | October 2024 | Abandon | 25 | 2 | 0 | Yes | No |
| 17941093 | MEDICAL GRADE NANOFIBRILLAR CELLULOSE HYDROGEL, A METHOD FOR TREATING A SUBJECT IN NEED OF TREATMENT OF BODY WITH IMPLANTABLE MATERIAL AND A METHOD FOR MANUFACTURING THE MEDICAL GRADE NANOFIBRILLAR CELLULOSE HYDROGEL | September 2022 | March 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17895951 | SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR | August 2022 | May 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17820781 | METHOD OF MANUFACTURING PHARMACEUTICAL COMPOSITIONS | August 2022 | August 2023 | Abandon | 12 | 1 | 0 | No | No |
| 17881390 | ORALLY DISINTEGRATING TABLET COMPRISING AMORPHOUS SOLID DISPERSION OF NILOTINIB AND IN VITRO CHARACTERIZATION THEREOF | August 2022 | October 2024 | Abandon | 26 | 2 | 0 | Yes | No |
| 17814128 | DELIVERY OF BIOLOGICS VIA MINERAL CRYSTALS FOR REGENERATIVE MEDICINE APPLICATIONS | July 2022 | December 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17861204 | ENVIRONMENTALLY BIODEGRADABLE MICROCAPSULES | July 2022 | November 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17838344 | ORAL NOURISHING COMPOSITION AND METHODS THEREOF | June 2022 | July 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17731905 | POROUS SILICATE AND/OR ALUMINOSILICATE MATRIX/CERIUM OXIDE NANOPARITLE NANOCARRIER FOR COMBINATION ANTI-CANCER THERAPEUTIC AND ANTIOXIDANT DELIVERY | April 2022 | September 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17724166 | RESIN COMPOSITIONS COMPRISING A MACROMOLECULE CROSSLINKED WITH POLYAMIDE EPICHLOROHYDRIN, CONTROLLED RELEASE PARTICLES AND COMPOSITIONS COMPRISING SAME, AND METHODS OF MAKING SAME | April 2022 | April 2025 | Abandon | 36 | 3 | 1 | Yes | No |
| 17724141 | MICROCAPSULES COMPRISING NATURAL MATERIALS | April 2022 | November 2023 | Allow | 19 | 1 | 1 | No | No |
| 17720656 | SUGAR COMPOSITIONS FOR TABLETING BY DIRECT COMPRESSION | April 2022 | February 2024 | Allow | 22 | 2 | 0 | No | No |
| 17712741 | POLYUREA CAPSULES PREPARED WITH A POLYISOCYANATE AND CROSS-LINKING AGENT | April 2022 | October 2023 | Abandon | 18 | 1 | 1 | No | No |
| 17763470 | ADHESIVE SILICONE PATTERN MATERIAL, AND WEAR COMPRISING SAME | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17684954 | FORMULATIONS OF A COMPOUND MODULATING KINASES | March 2022 | September 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17639385 | MICROCAPSULE AND HAIR CARE COMPOSITION | March 2022 | September 2024 | Allow | 31 | 3 | 0 | No | No |
| 17581665 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODS | January 2022 | May 2023 | Allow | 16 | 1 | 0 | No | No |
| 17573235 | COMPOSITIONS AND METHODS FOR INTRACELLULAR IRON DISPLACEMENT PROTEINS | January 2022 | March 2024 | Abandon | 26 | 2 | 0 | Yes | No |
| 17566752 | MESOPOROUS SPONGE SPICULE AND METHODS THEREOF | December 2021 | June 2025 | Allow | 41 | 3 | 0 | Yes | No |
| 17561782 | EXTENDED RELEASE GASTRORETENTIVE FORMULATION AGAINST HELICOBACTER PYLORI | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17619641 | COMPOSITION FOR SKIN WHITENING, COMPRISING CARVONE OR SALT THEREOF AS ACTIVE INGREDIENT | December 2021 | November 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17644612 | PHARMACEUTICAL COMPOSITION, COMPRISING PHOSPHATE BINDER PARTICLES | December 2021 | August 2022 | Allow | 7 | 1 | 0 | No | No |
| 17644599 | METHOD OF MANUFACTURING PHARMACEUTICAL COMPOSITIONS | December 2021 | August 2022 | Allow | 7 | 1 | 0 | No | No |
| 17596509 | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF GEL CONTAINING XYLOGLUCAN AND ALCOHOLS FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS | December 2021 | April 2025 | Abandon | 40 | 3 | 1 | No | No |
| 17615122 | CELL ACTIVATOR OF ANIMAL CELL | November 2021 | September 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17614644 | FILM-FORMING COMPOSITION CONTAINING GELLAN GUM AND STARCH, AND APPLICATION IN SOFT CAPSULE | November 2021 | February 2026 | Allow | 51 | 5 | 1 | Yes | No |
| 17613652 | METHODS OF TREATING URINARY SYSTEM CANCERS | November 2021 | January 2026 | Abandon | 50 | 2 | 0 | No | No |
| 17611659 | HYDROGEL FOR IN-VIVO RELEASE OF MEDICATION | November 2021 | April 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17454677 | SURFACE TREATMENT ARTICLES, DEVICES AND METHODS FOR MAKING THE SAME | November 2021 | November 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17610810 | METHOD OF MANUFACTURING ANTIVIRAL FIBER PRODUCT AND ANTIVIRAL MASK CONTAINING THE PRODUCT | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17517816 | ENVIRONMENTALLY BIODEGRADABLE MICROCAPSULES | November 2021 | February 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17594878 | Oral Compositions And Methods Of Use | November 2021 | December 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17504913 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODS | October 2021 | May 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17499511 | UTILIZATION OF BLOOD COMPONENT-CONTAINING SOLUTIONS FOR BIOPROSTHETIC VALVE MANUFACTURE AND TESTING | October 2021 | November 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17602814 | COSMETIC PRODUCT FOR HAIR CARE | October 2021 | January 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17601881 | HYALURONIC ACID-BASED DISSOLVING FILM, PRODUCTION METHOD THEREOF, AND RELEASE LINER USED FOR THE SAME | October 2021 | March 2025 | Allow | 41 | 1 | 1 | No | No |
| 17601401 | METHOD FOR TREATING KERATIN MATERIAL | October 2021 | October 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17601011 | METHOD FOR TREATING KERATIN MATERIAL | October 2021 | November 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17473180 | POLYUREA AND POLY(BETA-AMINO ESTER) CAPSULES WITH ENHANCED DEGRADABILITY | September 2021 | November 2023 | Allow | 26 | 2 | 1 | Yes | No |
| 17438064 | METHOD FOR IMPROVING THE PERFORMANCE OF A FRAGRANCE OR A FRAGRANCE MIXTURE | September 2021 | September 2024 | Abandon | 36 | 2 | 1 | Yes | No |
| 17472384 | TWO SPEED MONOLITHIC SYSTEM FOR CONTROLLED RELEASE OF DRUGS | September 2021 | April 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17437067 | Hyaluronic Acid Derivatives for Wound Healing | September 2021 | April 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17431238 | POLYURETHANE FOR COSMETIC PREPARATIONS, AND METHOD FOR PRODUCING POLYURETHANE FOR COSMETIC PREPARATIONS | August 2021 | January 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17374986 | Edible Graphic Drug Delivery System and Method of Manufacture | July 2021 | July 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17370615 | TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE (AD) | July 2021 | September 2023 | Allow | 26 | 2 | 0 | No | No |
| 17351338 | CANNABINOID SYRUP AND METHODS FOR MAKING AND USING SAME | June 2021 | January 2025 | Abandon | 43 | 4 | 0 | No | No |
| 17416099 | PROTEIN MICROCAPSULES AND METHOD OF PREPARING THE SAME | June 2021 | May 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17416084 | MICROCAPSULE COMPOSITIONS | June 2021 | December 2024 | Allow | 42 | 1 | 1 | No | No |
| 17416080 | GUAR GUM MICROCAPSULES | June 2021 | May 2025 | Allow | 47 | 2 | 1 | No | No |
| 17416085 | MICROCAPSULE COMPOSITIONS PREPARED FROM POLYSACCHARIDES | June 2021 | March 2024 | Allow | 33 | 2 | 0 | Yes | No |
| 17416090 | HYDROXYETHYL CELLULOSE MICROCAPSULES | June 2021 | February 2025 | Allow | 44 | 1 | 1 | No | No |
| 17416096 | MICROCAPSULES PREPARED FROM PROTEINS | June 2021 | September 2025 | Allow | 51 | 2 | 1 | No | No |
| 17414663 | COMPOSITION | June 2021 | December 2024 | Abandon | 42 | 2 | 1 | Yes | No |
| 17304181 | SKIN LIGHTENING COMPOSTIONS | June 2021 | January 2025 | Abandon | 43 | 4 | 0 | No | Yes |
| 17346402 | Method of Dispersing Hydrophobic Substances in Aqueous Cleansing System | June 2021 | January 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17299198 | PROCESS FOR PREPARING A SURFACE WITH BACTERIOSTATIC ACTIVITY AND SURFACE THUS PREPARED | June 2021 | April 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17328548 | ORALLY DISINTEGRATING TABLET COMPRISING AMORPHOUS SOLID DISPERSION OF NILOTINIB | May 2021 | November 2022 | Allow | 18 | 3 | 0 | Yes | No |
| 17328685 | SEMI-SOLID TOPICAL COMPOSITION CONTAINING PIRFENIDONE AND MODIFIED DIALLYL DISULFIDE OXIDE (M-DDO) FOR ELIMINATING OR PREVENTING ACNE | May 2021 | May 2023 | Allow | 24 | 2 | 0 | No | No |
| 17328041 | CANCER TREATMENT | May 2021 | March 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17307466 | TEXTURIZED INSECTICIDAL FORMULATION | May 2021 | October 2024 | Abandon | 41 | 4 | 0 | Yes | No |
| 17245360 | Stem Cell Stimulating Compositions for Treatment of Melasma | April 2021 | September 2023 | Allow | 29 | 2 | 0 | No | No |
| 17240363 | BIOERODIBLE DRUG DELIVERY IMPLANTS | April 2021 | December 2024 | Allow | 43 | 3 | 1 | No | No |
| 17238037 | TOPICAL PREPARATIONS OF DRUG DELIVERY FOR NASAL AND SINUS IRRIGATION | April 2021 | August 2024 | Abandon | 40 | 3 | 0 | Yes | No |
| 17287337 | DRUG CONJUGATE PREPARED USING ALDEHYDE GROUP AT END OF HYALURONIC ACID | April 2021 | April 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17286089 | COMPOSITION AND METHODS FOR IMPARTING A LIKING, CARING OR FRESH ATTRIBUTE | April 2021 | January 2025 | Abandon | 45 | 2 | 1 | Yes | No |
| 17285796 | COMPOSITE FABRIC OF WATER RETENTIVE AND ANTIMICROBIAL MATERIALS FOR SUSTAINED SKIN HYDRATION | April 2021 | June 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17285181 | TRANSDERMAL TROPANE COMPOSITIONS AND METHODS FOR USING THE SAME | April 2021 | June 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17282430 | COMPOSITIONS AND METHODS FOR PROMOTING AND MAINTAINING ORAL HEALTH | April 2021 | November 2024 | Abandon | 44 | 2 | 0 | No | No |
| 17282089 | SLURRY AND SOLUTION COMPOSITIONS | April 2021 | May 2023 | Abandon | 25 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PHAN, DOAN THI-THUC.
With a 28.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PHAN, DOAN THI-THUC works in Art Unit 1613 and has examined 634 patent applications in our dataset. With an allowance rate of 42.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner PHAN, DOAN THI-THUC's allowance rate of 42.4% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PHAN, DOAN THI-THUC receive 2.74 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PHAN, DOAN THI-THUC is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +54.6% benefit to allowance rate for applications examined by PHAN, DOAN THI-THUC. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.3% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 17.6% of cases where such amendments are filed. This entry rate is in the 20% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 29.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 31% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 54.9% of appeals filed. This is in the 26% percentile among all examiners. Of these withdrawals, 33.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 68.3% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.